Skip to main content
. 2017 Jan 16;23(14):1909–1917. doi: 10.1177/1352458516688956

Figure 2.

Figure 2.

Gadolinium-enhancing lesion number.

Mean (SEM) number of new and persisting gadolinium-enhancing lesions during open-label extension part of the trial.